Abstract
AbstractPancreatic cancer is a devastating disease often detected at later stages, necessitating swift and effective chemotherapy treatment. However, chemoresistance is common and its mechanisms are poorly understood. Here, label-free multi-modal nonlinear optical microscopy was applied to study microstructural and functional features of pancreatic tumors in vivo to monitor inter- and intra-tumor heterogeneity and treatment response. Patient-derived xenografts with human pancreatic ductal adenocarcinoma were implanted into mice and characterized over five weeks of intraperitoneal chemotherapy (FIRINOX or Gem/NabP) with known responsiveness/resistance. Resistant and responsive tumors exhibited a similar initial metabolic response, but by week 5 the resistant tumor deviated significantly from the responsive tumor, indicating that a representative response may take up to five weeks to appear. This biphasic metabolic response in a chemoresistant tumor reveals the possibility of intra-tumor spatiotemporal heterogeneity of drug responsiveness. These results, though limited by small sample size, suggest the possibility for further work characterizing chemoresistance mechanisms using nonlinear optical microscopy.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering
Mayo Clinic & Illinois Alliance for Technology-Based Healthcare
Publisher
Springer Science and Business Media LLC
Subject
General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference51 articles.
1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
2. Ansari, D. et al. Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol. 12, 1929–1946 (2016).
3. Binenbaum, Y., Na’ara, S. & Gil, Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist. Updat. 23, 55–68 (2015).
4. Kim, M. P. & Gallick, G. E. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin. Cancer Res. 14, 1284–1285 (2008).
5. Narayanan, S., Vicent, S. & Ponz-Sarvisé, M. PDAC as an immune evasive disease: Can 3D model systems aid to tackle this clinical problem? Front. Cell Dev. Biol. 9, 787249 (2021).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献